Market closedADR
Cellectis/$CLLS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Cellectis
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
Ticker
$CLLS
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
219
Website
Cellectis Metrics
BasicAdvanced
$175M
Market cap
-
P/E ratio
-$1.04
EPS
3.20
Beta
-
Dividend rate
Price and volume
Market cap
$175M
Beta
3.2
52-week high
$3.77
52-week low
$1.70
Average daily volume
79K
Financial strength
Current ratio
1.777
Quick ratio
1.737
Long term debt to equity
28.343
Total debt to equity
39.051
Interest coverage (TTM)
-7.18%
Management effectiveness
Return on assets (TTM)
-16.09%
Return on equity (TTM)
-82.20%
Valuation
Price to revenue (TTM)
3.997
Price to book
1.29
Price to tangible book (TTM)
1.3
Price to free cash flow (TTM)
2.386
Growth
Revenue change (TTM)
46.96%
Earnings per share change (TTM)
-37.35%
3-year revenue growth (CAGR)
-18.99%
3-year earnings per share growth (CAGR)
-29.22%
What the Analysts think about Cellectis
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Cellectis stock.
Cellectis Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Cellectis Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Cellectis News
AllArticlesVideos
Cellectis: Poised To Start Answering Questions In 2025
Seeking Alpha·3 days ago
Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB)
GlobeNewsWire·5 days ago
Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Cellectis stock?
Cellectis (CLLS) has a market cap of $175M as of December 15, 2024.
What is the P/E ratio for Cellectis stock?
The price to earnings (P/E) ratio for Cellectis (CLLS) stock is 0 as of December 15, 2024.
Does Cellectis stock pay dividends?
No, Cellectis (CLLS) stock does not pay dividends to its shareholders as of December 15, 2024.
When is the next Cellectis dividend payment date?
Cellectis (CLLS) stock does not pay dividends to its shareholders.
What is the beta indicator for Cellectis?
Cellectis (CLLS) has a beta rating of 3.2. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.